tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
AIDS-Associated Nephropathy D016263 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Vestibular Diseases D015837 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
HIV Infections D015658 20 associated lipids
Histiocytosis D015614 2 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Reperfusion Injury D015427 65 associated lipids
Scleritis D015423 3 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Discitis D015299 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Dementia, Vascular D015140 7 associated lipids
Wounds, Stab D014951 3 associated lipids
West Nile Fever D014901 1 associated lipids
Vomiting D014839 21 associated lipids
Vitiligo D014820 2 associated lipids
Vision Disorders D014786 10 associated lipids
Viremia D014766 4 associated lipids
Venous Insufficiency D014689 2 associated lipids
Vasculitis D014657 14 associated lipids
Vascular Diseases D014652 16 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hernández D et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. 2007 Transplantation pmid:17893603
Connor A et al. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. 2012 Transplantation pmid:23318306
Gurk-Turner C et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. 2008 Transplantation pmid:18497682
Khanafer A et al. Increased nitric oxide production during acute rejection in kidney transplantation: a useful marker to aid in the diagnosis of rejection. 2007 Transplantation pmid:17876269
Yang CW et al. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. 2001 Transplantation pmid:11740384
Benito N et al. Alternariosis after liver transplantation. 2001 Transplantation pmid:11740399
Hirose R et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. 2000 Transplantation pmid:10670644
Han DH et al. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. 2010 Transplantation pmid:20562737
Schäffer MR et al. Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. 1998 Transplantation pmid:9539093
Kim CD et al. Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. 2010 Transplantation pmid:20842074
Demmers MW et al. Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. 2014 Transplantation pmid:24704664
Jain A et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. 2000 Transplantation pmid:11087149
Shibutani S et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. 2005 Transplantation pmid:15849542
Lee CM et al. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. 1997 Transplantation pmid:9371670
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Tory R et al. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. 2009 Transplantation pmid:19584682
Manitpisitkul W et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. 2009 Transplantation pmid:19584685
Fujimura Y and Owen RL Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit Peyer's patches. 2002 Transplantation pmid:11965030
Weiler N et al. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. 2010 Transplantation pmid:21048536
Tanabe M et al. Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. 1994 Transplantation pmid:7518619
Wang SC et al. A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. 1993 Transplantation pmid:7692640
Bozorgzadeh A et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. 2004 Transplantation pmid:15087773
Barraclough KA et al. NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. 2012 Transplantation pmid:23095803
Diem HV et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. 2003 Transplantation pmid:12777858
Smets F et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. 2002 Transplantation pmid:12042647
Heidt S et al. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. 2008 Transplantation pmid:19005412
Serón D et al. Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients. 2007 Transplantation pmid:17353788
Vennarecci G et al. Apoptosis and rejection in rat intestinal transplantation: correlation with FK506 doses and donor specific bone marrow infusions. 2001 Transplantation pmid:11455248
Imado T et al. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. 2004 Transplantation pmid:14966413
Gill JS et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. 2010 Transplantation pmid:20098280
Wallia A et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. 2010 Transplantation pmid:20098286
Schulman SL et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. 1998 Transplantation pmid:9625026
Pascual J et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 2009 Transplantation pmid:19136902
Hayashi S et al. Effect of adenovirus-mediated transfer of the CTLA4IG gene in hamster-to-rat xenotransplantation. 2005 Transplantation pmid:16123724
Pacifico L et al. Tacrolimus and food allergy. 2003 Transplantation pmid:14688538
Gullestad L et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. 2010 Transplantation pmid:20061999
Glicklich D et al. Chronic renal allograft rejection: no response to mycophenolate mofetil. 1998 Transplantation pmid:9721811
Ciancio G et al. Review of major clinical trials with mycophenolate mofetil in renal transplantation. 2005 Transplantation pmid:16251852
Tamura K et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. 1995 Transplantation pmid:7539960
Shaefer MS et al. Falsely elevated FK-506 levels caused by sampling through central venous catheters. 1993 Transplantation pmid:7689264
Valdivia LA et al. Dendritic cell replacement in long-surviving liver and cardiac xenografts. 1993 Transplantation pmid:7689265
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplantation pmid:12499885
Jordan ML et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. 1997 Transplantation pmid:9020321
Mazariegos GV et al. Weaning of immunosuppression in liver transplant recipients. 1997 Transplantation pmid:9020325
Tsugita M et al. Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. 1996 Transplantation pmid:8685952
Lake JR et al. The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. 1995 Transplantation pmid:7482713
Nakazawa Y et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. 1998 Transplantation pmid:9808496
de Jonge H et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. 2010 Transplantation pmid:20592652
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
Shibasaki S et al. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. 2013 Transplantation pmid:23269193